Atossa updates corporate presentation on (Z)-Endoxifen, but no specifics disclosed

ATOSSA THERAPEUTICS, INC.

Filed updated corporate presentation on 8-K Sept 18, 2026; no financial or clinical data shown.
Presentation cover cites (Z)-Endoxifen as potential best-in-class oral SERM/SERD for estrogen-driven diseases.
Available exhibit excerpt contains only the title slide; operational milestones or guidance not provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.